In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice
- PMID: 11231629
- DOI: 10.1038/85454
In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice
Abstract
Metachromatic leukodystrophy (MLD) is a lipidosis caused by deficiency of arylsulfatase A (ARSA). Although the genetics of MLD are known, its pathophysiology is not understood. The disease leads to progressive demyelination and early death and no effective treatment is available. We used lentiviral vectors to deliver a functional ARSA gene (human ARSA) into the brain of adult mice with germ-line inactivation of the mouse gene encoding ARSA, As2. We report sustained expression of active enzyme throughout a large portion of the brain, with long-term protection from development of neuropathology and hippocampal-related learning impairments. We show that selective degeneration of hippocampal neurons is a central step in disease pathogenesis, and provide evidence that in vivo transfer of ARSA by lentiviral vectors reverts the disease phenotype in all investigated areas. Therefore, in vivo gene therapy offers a unique option for MLD and other storage diseases affecting the central nervous system.
Similar articles
-
Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access.Lancet. 2022 Jan 22;399(10322):372-383. doi: 10.1016/S0140-6736(21)02017-1. Lancet. 2022. PMID: 35065785 Free PMC article. Clinical Trial.
-
Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy.Hum Gene Ther. 2007 Sep;18(9):821-36. doi: 10.1089/hum.2007.048. Hum Gene Ther. 2007. PMID: 17845130
-
Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy.Mol Ther. 2015 Sep;23(9):1519-31. doi: 10.1038/mt.2015.106. Epub 2015 Jun 10. Mol Ther. 2015. PMID: 26061647 Free PMC article.
-
Gene therapy in metachromatic leukodystrophy.Int J Clin Pharmacol Ther. 2009;47 Suppl 1:S128-31. doi: 10.5414/cpp47128. Int J Clin Pharmacol Ther. 2009. PMID: 20040324 Review.
-
Atidarsagene autotemcel for metachromatic leukodystrophy.Drugs Today (Barc). 2023 Feb;59(2):63-70. doi: 10.1358/dot.2023.59.2.3461911. Drugs Today (Barc). 2023. PMID: 36811406 Review.
Cited by
-
CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder.PLoS One. 2012;7(1):e30341. doi: 10.1371/journal.pone.0030341. Epub 2012 Jan 18. PLoS One. 2012. PMID: 22279584 Free PMC article.
-
Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors.Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6216-21. doi: 10.1073/pnas.082011999. Epub 2002 Apr 16. Proc Natl Acad Sci U S A. 2002. PMID: 11959904 Free PMC article.
-
A lentiviral gene therapy strategy for the in vitro production of feline erythropoietin.PLoS One. 2012;7(9):e45099. doi: 10.1371/journal.pone.0045099. Epub 2012 Sep 18. PLoS One. 2012. PMID: 23028782 Free PMC article.
-
Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration.J Neurosci. 2002 Jun 1;22(11):4478-86. doi: 10.1523/JNEUROSCI.22-11-04478.2002. J Neurosci. 2002. PMID: 12040055 Free PMC article.
-
Gene therapy: prospects for glycolipid storage diseases.Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):921-5. doi: 10.1098/rstb.2003.1277. Philos Trans R Soc Lond B Biol Sci. 2003. PMID: 12803926 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical